


- Tricyclic diterpenoid first isolated in 1951 from fungi of the *Clitopilus* genus


- Potent inhibitor of bacterial protein synthesis by binding to the bacterial ribosome.

- Modification of ester functionality (**R**) gives semisynthetic pleuromutilin derivatives, some of which are FDA-approved antibiotics


Nicholas J. Foy and Sergey V. Pronin*, JACS **2022**, 144, 10174









pleuromutilin derivatives:




retapamulin (GSK), approved in 2007
for topical treatment of skin infections





lefamulin (Nabriva), approved in 2019
for systematic treatment of bacterial
infections in humans






- a) LDA, TIPSOT
- b) PPTS
- c) LDA, Et₂O, **9**



reaction name?









- Tricyclic diterpenoid first isolated in 1951 from fungi of the *Clitopilus* genus


- Potent inhibitor of bacterial protein synthesis by binding to the bacterial ribosome.

- Modification of ester functionality (**R**) gives semisynthetic pleuromutilin derivatives, some of which are FDA-approved antibiotics

Nicholas J. Foy and Sergey V. Pronin*, JACS **2022**, *144*, 10174



retapamulin (GSK), approved in 2007 for topical treatment of skin infections



lefamulin (Nabriva), approved in 2019 for systematic treatment of bacterial infections in humans

